ANI Pharmaceuticals reports Q2 adjusted EPS $1.28, consensus 68c

Reports Q2 revenue $116.5M, consensus $98.7M. “The Q2 was another strong quarter for ANI, across all areas of the business. The Company is proud to report record net revenues and adjusted non-GAAP EBITDA and raise FY23 guidance for the Q2 in a row. With record quarterly new patient starts, new cases initiated, new unique prescribers, and ongoing growth in repeat prescribers, the launch momentum for Purified Cortrophin Gel remains strong. In addition, the overall ACTH category is robust, with year-on-year growth in volumes every month during the first half of 2023. Following our recent successful equity raise and based on strong cash flow generation from operating activities, we believe ANI is well-positioned to seek opportunities to increase the scope and scale of our Rare Disease portfolio through M&A and in-licensing,” stated Nikhil Lalwani, President and CEO of ANI.